Free Trial

Avenue Therapeutics (ATXI) Competitors

Avenue Therapeutics logo
$0.73 -0.01 (-1.34%)
As of 10/17/2025 12:33 PM Eastern

ATXI vs. KPRX, ALBT, TNFA, GOVX, CELZ, GNPX, HCWB, BCTX, QLGN, and CYCN

Should you be buying Avenue Therapeutics stock or one of its competitors? The main competitors of Avenue Therapeutics include Kiora Pharmaceuticals (KPRX), Avalon GloboCare (ALBT), TNF Pharmaceuticals (TNFA), GeoVax Labs (GOVX), Creative Medical Technology (CELZ), Genprex (GNPX), HCW Biologics (HCWB), Briacell Therap (BCTX), Qualigen Therapeutics (QLGN), and Cyclerion Therapeutics (CYCN). These companies are all part of the "pharmaceutical products" industry.

Avenue Therapeutics vs. Its Competitors

Avenue Therapeutics (NASDAQ:ATXI) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

In the previous week, Avenue Therapeutics and Avenue Therapeutics both had 2 articles in the media. Kiora Pharmaceuticals' average media sentiment score of 0.50 beat Avenue Therapeutics' score of 0.00 indicating that Kiora Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Avenue Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Kiora Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Kiora Pharmaceuticals' return on equity of -47.17% beat Avenue Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Avenue TherapeuticsN/A -471.57% -296.50%
Kiora Pharmaceuticals N/A -47.17%-34.00%

Kiora Pharmaceuticals has a consensus target price of $10.00, suggesting a potential upside of 269.00%. Given Kiora Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Kiora Pharmaceuticals is more favorable than Avenue Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avenue Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Kiora Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

17.3% of Avenue Therapeutics shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 1.8% of Avenue Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Kiora Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Avenue Therapeutics has a beta of 0.04, meaning that its share price is 96% less volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals has a beta of -0.67, meaning that its share price is 167% less volatile than the S&P 500.

Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avenue TherapeuticsN/AN/A-$10.38M-$0.95-0.77
Kiora PharmaceuticalsN/AN/A$3.60M-$2.91-0.93

Summary

Kiora Pharmaceuticals beats Avenue Therapeutics on 8 of the 12 factors compared between the two stocks.

Get Avenue Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ATXI vs. The Competition

MetricAvenue TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.36M$1.01B$6.10B$10.50B
Dividend YieldN/A4.84%5.73%4.81%
P/E Ratio0.041.2584.5227.09
Price / SalesN/A145.12585.94210.58
Price / CashN/A17.6337.1661.22
Price / Book0.388.0312.246.52
Net Income-$10.38M-$7.71M$3.32B$276.75M
7 Day Performance2.82%0.17%1.25%2.00%
1 Month Performance-14.11%29.02%6.28%2.26%
1 Year Performance-65.40%-12.50%59.92%35.58%

Avenue Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ATXI
Avenue Therapeutics
2.1164 of 5 stars
$0.73
-1.3%
N/A-63.3%$2.36MN/A0.044News Coverage
Gap Up
KPRX
Kiora Pharmaceuticals
3.1152 of 5 stars
$2.73
-0.4%
$10.00
+266.3%
-18.6%$9.36M$16.02M-0.9410News Coverage
Positive News
Short Interest ↓
ALBT
Avalon GloboCare
0.8947 of 5 stars
$2.39
+2.1%
N/A-15.2%$9.18M$1.33M-0.125
TNFA
TNF Pharmaceuticals
0.0588 of 5 stars
$4.90
-14.8%
N/A-96.9%$9.05MN/A-0.026
GOVX
GeoVax Labs
2.2949 of 5 stars
$0.55
-3.9%
$8.50
+1,438.2%
-72.5%$8.80M$6.14M-0.2710News Coverage
Analyst Revision
Gap Down
CELZ
Creative Medical Technology
1.4068 of 5 stars
$3.41
+0.9%
N/A-13.3%$8.80M$6K-1.075Analyst Forecast
GNPX
Genprex
2.1616 of 5 stars
$0.20
-1.0%
N/A+6.8%$8.68MN/A0.0020News Coverage
Analyst Upgrade
Short Interest ↓
Gap Down
HCWB
HCW Biologics
2.1852 of 5 stars
$4.03
flat
$35.00
+768.5%
-82.2%$8.66M$2.57M-0.2940News Coverage
Short Interest ↓
BCTX
Briacell Therap
1.3308 of 5 stars
$12.63
-4.5%
$320.00
+2,433.7%
-90.7%$8.59MN/A-0.158Short Interest ↑
QLGN
Qualigen Therapeutics
N/A$5.03
flat
N/A-54.6%$8.53MN/A0.0050Short Interest ↑
CYCN
Cyclerion Therapeutics
0.8053 of 5 stars
$2.55
+6.7%
N/A-15.5%$8.51M$2.17M-3.4530Analyst Forecast
Short Interest ↑
Gap Down

Related Companies and Tools


This page (NASDAQ:ATXI) was last updated on 10/18/2025 by MarketBeat.com Staff
From Our Partners